Liaoning He Eye Hospital Group (301103.SZ) issues a profit warning, expecting a net loss of 20.5 million to 30.75 million yuan in 2024, turning from profit to loss.
He Medical Ophthalmology (301103.SZ) released the 2024 annual performance forecast, with the company expecting...
Liaoning He Eye Hospital Group (301103.SZ) released the performance forecast for the year 2024, with the company expecting a net loss attributable to shareholders of the listed company of 20.5 million yuan to 30.75 million yuan, a switch from profit to loss; a net loss of 22 million yuan to 32.5 million yuan after deducting non-recurring gains and losses, also a switch from profit to loss.
During the reporting period, intensified industry competition and the impact of healthcare payment reform caused a decrease in the company's revenue and gross profit. The company has invested heavily in innovative business, digitalization, and R&D projects, resulting in increased cost and expense compared to the same period last year.
Related Articles

Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.

RECOMMEND

General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025

Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025

Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025